Kazatchkine M, Mouthon L, Kaveri S V
Service d'Immunologie et INSERM U430, Hôpital Broussais et Université Pierre-et-Marie-Curie, Paris.
Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S13-8.
Intravenous immunoglobulin (IVIg) has been used for many years in the treatment of primary and secondary antibody deficiencies. IVIg was first demonstrated to be effective in auto-immune desorders twenty years ago in the treatment of idiopathic thrombocytopenic purpura. The beneficial effect of IVIg has since been established in the Guillain-Barré syndrome, chronic inflammatory demenilating polyneuropathy, myasthenia gravis, dermatomyositis, Kawasaki syndrome and graft versus host disease. The beneficial effect of IVIg has been suggested in a large number of other auto-immune and systemic inflammatory conditions. The mode of action of IVIg is complex, involving Fc receptor blockade, interference with complement activation and the cytokine network, provision of anti-idiotypic antibodies and modulation of T and B cell activation and differentiation. Such a broad range of activities reflects the function of normal circulating immunoglobulins in maintaining tolerance to self in healthy individuals.
静脉注射免疫球蛋白（IVIg）多年来一直用于治疗原发性和继发性抗体缺陷。二十年前，IVIg首次被证明在自身免疫性疾病中对特发性血小板减少性紫癜有效。此后，IVIg在格林-巴利综合征、慢性炎症性脱髓鞘性多发性神经病、重症肌无力、皮肌炎、川崎病和移植物抗宿主病中的有益作用得到确立。在大量其他自身免疫性和全身性炎症性疾病中也提示了IVIg的有益作用。IVIg的作用方式很复杂，包括Fc受体阻断、干扰补体激活和细胞因子网络、提供抗独特型抗体以及调节T和B细胞的激活与分化。如此广泛的活性反映了正常循环免疫球蛋白在健康个体中维持自身耐受性的功能。
